MoonLake Immunotherapeutics

MLTX

$11.91

Updated: 25/09/2026, 16:46:34

Market Cap

$999.96M

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for MLTX

Company Profile

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

USD

NASDAQ

CEO: Jorge Santos da Silva

Employees: 130

https://www.moonlaketx.com

Asset Summaries

Latest generated summaries for MLTX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for MLTX.

Share price: $11.91
Market cap: $999.96M
Exchange: NASDAQ
Currency: USD
CEO: Jorge Santos da Silva
Employees: 130
IPO date: 20/10/2020
Beta: 1.041
Last dividend: $0.00
Day range: $11.80 – $12.21
52-week range: $5.95 – $62.75
1-day performance: -1.73%
1-year performance: 100.17%
Current drawdown (1Y): -81.02%
CIK: 0001821586
CUSIP: 61559X104
ISIN: KY61559X1045
Created: 07/12/2025, 05:16:38
Last update: 25/09/2026, 16:46:34

Track MoonLake Immunotherapeutics with an AI analyst

See which prediction-market events move MLTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to MLTX from your Railway `news_articles` table.

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

GlobeNewsWire • STOCK • 10/05/2026, 11:00:00

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

The Motley Fool • STOCK • 18/04/2026, 12:17:01

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

GlobeNewsWire • STOCK • 28/03/2026, 16:00:00

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

The Motley Fool • STOCK • 16/03/2026, 20:36:24

Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX

Defense World • STOCK • 14/03/2026, 04:07:16

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

Seeking Alpha • STOCK • 23/02/2026, 16:24:57

BioTech Breakout: MoonLake Up 30% On FDA Wins

MarketBeat • STOCK • 03/02/2026, 16:48:20